Natural and designer binding sites made by phage display technology.
In the past decade, the drive to develop completely human antibodies for human therapy has led to the development of phage display technology. This technology is able to deliver the ultimate in antibody engineering, that is, high-affinity fully human antibodies to any antigen of choice. Here, this application of phage display technology is reviewed, and the many other antibody-engineering avenues this technology offers are highlighted.
Target Quest BV, a subsidiary of Dyax Corp, PO Box 5800, 6202 AZ Maastricht, The Netherlands. hhoogenboom@targetquest.nl
H R
HR
Hoogenboom
P
P
Chames
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000737:chemistry*; D001419:Bacteria / Q000235:genetics / Q000378:metabolism; D001666:Binding Sites, Antibody; D001709:Biotechnology / Q000379:methods*; D006801:Humans; D007135:Immunoglobulin Variable Region; D019151:Peptide Library; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry; D012270:Ribosomes / Q000235:genetics / Q000378:metabolism; D015003:Yeasts / Q000235:genetics / Q000378:metabolism
D000911:Antibodies, Monoclonal; D007135:Immunoglobulin Variable Region; D019151:Peptide Library; D011994:Recombinant Proteins